United Therapeutics Q3 Net Income Falls 24% to $258.6 Million
Bitget2026/11/04 11:34- United Therapeutics’ third-quarter 2026 diluted earnings per share fell 20% year-over-year to $5.71.
- Total revenues rose to $832.5 million, while Tyvaso DPI revenues climbed 13% to $378.5 million.
- Research and development expense more than doubled to $279.2 million, partly due to acquisition-related research costs for Thymmune.
- The board authorized a new $2 billion share repurchase program in October 2026, running through October 21, 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
U.S. commercial crude oil inventories have declined for five consecutive weeks, while diesel inventories have fallen below 100 million barrels, reaching their lowest level since 2003.
EIA data shows that U.S. commercial crude oil inventories fell by 865,000 barrels last week to 409.8 million barrels, about 4% below the five-year seasonal average. The market had previously expected a decrease of around 200,000 barrels. Distillate fuel (including diesel and heating oil) inventories decreased by 3.6 million barrels to 99.3 million barrels, 13% below the five-year average. The market had previously expected a decline of only around 1 million barrels, making the actual reduction much greater than anticipated.
This Blockchain Is Abandoning Its Own Network—It Has Issued an Official Statement Regarding the Switch to Another Network
Crypto prices
More
